Precision Medicine in AD: Castle Biosciences’ Pipeline AD Test Aims to Change the Way Your Patients Are Treated
Derek Maetzold, President and Chief Executive Officer of Castle Biosciences, reviews the 487-gene expression profile test’s power and promise.